Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PIK3CA H1047R
i
Other names:
PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5290
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
therascreen® PIK3CA RGQ PCR Kit (3)
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
therascreen® PIK3CA RGQ PCR Kit (3)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
alpelisib
Sensitive: C2 – Inclusion Criteria
alpelisib
Sensitive
:
C2
PIK3CA H1047R
Colorectal Cancer
PIK3CA H1047R
Colorectal Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
PIK3CA H1047R
HER2 Positive Breast Cancer
PIK3CA H1047R
HER2 Positive Breast Cancer
PF-05212384 + trastuzumab-pkrb
Sensitive: C3 – Early Trials
PF-05212384 + trastuzumab-pkrb
Sensitive
:
C3
PF-05212384 + trastuzumab-pkrb
Sensitive: C3 – Early Trials
PF-05212384 + trastuzumab-pkrb
Sensitive
:
C3
PIK3CA H1047R
Non Small Cell Lung Cancer
PIK3CA H1047R
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
trametinib + dabrafenib
Sensitive: C3 – Early Trials
trametinib + dabrafenib
Sensitive
:
C3
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
TAS-117
Sensitive: C3 – Early Trials
TAS-117
Sensitive
:
C3
TAS-117
Sensitive: C3 – Early Trials
TAS-117
Sensitive
:
C3
PIK3CA H1047R
Hormone Receptor Positive Breast Cancer
PIK3CA H1047R
Hormone Receptor Positive Breast Cancer
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
everolimus
Sensitive: C3 – Early Trials
everolimus
Sensitive
:
C3
PIK3CA H1047R
Melanoma
PIK3CA H1047R
Melanoma
dabrafenib
Sensitive: C4 – Case Studies
dabrafenib
Sensitive
:
C4
dabrafenib
Sensitive: C4 – Case Studies
dabrafenib
Sensitive
:
C4
PIK3CA H1047R
HER2 Positive Breast Cancer
PIK3CA H1047R
HER2 Positive Breast Cancer
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
trametinib + dabrafenib + everolimus
Sensitive
:
C4
trametinib + dabrafenib + everolimus
Sensitive: C4 – Case Studies
trametinib + dabrafenib + everolimus
Sensitive
:
C4
PIK3CA H1047R
Salivary Gland Cancer
PIK3CA H1047R
Salivary Gland Cancer
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
vandetanib
Sensitive: C4 – Case Studies
vandetanib
Sensitive
:
C4
PIK3CA H1047R
Colon Cancer
PIK3CA H1047R
Colon Cancer
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
trametinib
Sensitive: D – Preclinical
trametinib
Sensitive
:
D
PIK3CA H1047R
Endometrial Cancer
PIK3CA H1047R
Endometrial Cancer
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
PIK3CA H1047R
Colorectal Cancer
PIK3CA H1047R
Colorectal Cancer
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
trastuzumab + lapatinib
Resistant: D – Preclinical
trastuzumab + lapatinib
Resistant
:
D
trastuzumab + lapatinib
Resistant: D – Preclinical
trastuzumab + lapatinib
Resistant
:
D
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
trastuzumab + MEN1611
Sensitive: D – Preclinical
trastuzumab + MEN1611
Sensitive
:
D
trastuzumab + MEN1611
Sensitive: D – Preclinical
trastuzumab + MEN1611
Sensitive
:
D
PIK3CA H1047R
Breast Cancer
PIK3CA H1047R
Breast Cancer
GDC-0941
Sensitive: D – Preclinical
GDC-0941
Sensitive
:
D
GDC-0941
Sensitive: D – Preclinical
GDC-0941
Sensitive
:
D
PIK3CA H1047R
HER2 Positive Breast Cancer
PIK3CA H1047R
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: D – Preclinical
ado-trastuzumab emtansine
Sensitive
:
D
ado-trastuzumab emtansine
Sensitive: D – Preclinical
ado-trastuzumab emtansine
Sensitive
:
D
PIK3CA H1047R
Head and Neck Cancer
PIK3CA H1047R
Head and Neck Cancer
alpelisib
Sensitive: D – Preclinical
alpelisib
Sensitive
:
D
alpelisib
Sensitive: D – Preclinical
alpelisib
Sensitive
:
D
PIK3CA H1047R
Ovarian Cancer
PIK3CA H1047R
Ovarian Cancer
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
MEN1611
Sensitive: D – Preclinical
MEN1611
Sensitive
:
D
PIK3CA H1047R
Ovarian Cancer
PIK3CA H1047R
Ovarian Cancer
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
PIK3CA H1047R
Head and Neck Cancer
PIK3CA H1047R
Head and Neck Cancer
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
SHR-A1307
Sensitive: D – Preclinical
SHR-A1307
Sensitive
:
D
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA H1047R
HER2 Negative Breast Cancer
PIK3CA H1047R
HER2 Negative Breast Cancer
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
LX-086
Sensitive: D – Preclinical
LX-086
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
GDC-0941
Resistant: D – Preclinical
GDC-0941
Resistant
:
D
GDC-0941
Resistant: D – Preclinical
GDC-0941
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
BMS-722782
Resistant: D – Preclinical
BMS-722782
Resistant
:
D
BMS-722782
Resistant: D – Preclinical
BMS-722782
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PF-3845
Resistant: D – Preclinical
PF-3845
Resistant
:
D
PF-3845
Resistant: D – Preclinical
PF-3845
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PF-05212384
Sensitive: D – Preclinical
PF-05212384
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
cetuximab
Resistant: D – Preclinical
cetuximab
Resistant
:
D
cetuximab
Resistant: D – Preclinical
cetuximab
Resistant
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
PIK3CA H1047R
Thyroid Gland Carcinoma
PIK3CA H1047R
Thyroid Gland Carcinoma
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
temsirolimus + BAY86-9766
Sensitive: D – Preclinical
temsirolimus + BAY86-9766
Sensitive
:
D
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
PIK3CA H1047R
Squamous Cell Carcinoma of Head and Neck
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login